Malignancy Risk in Patients With Secukinumab-treated Psoriasis Malignancy Risk in Patients With Secukinumab-treated Psoriasis
Does treatment with secukinumab increase the risk of malignancy in patients being treated for psoriasis, psoriatic arthritis, or ankylosing spondylitis?The British Journal of Dermatology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
More News: Ankylosing Spondylitis | Arthritis | Cancer & Oncology | Dermatology | Health | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | UK Health